UPDATE: Morgan Stanley Raises PT to $83 on Celgene on Abraxane-Driven Growth Outlook
Morgan Stanley reiterated its Overweight rating on Celgene (NASDAQ: CELG) and raised its price target from $81 to $83.
Morgan Stanley commented, "Details are scant prior to an ASCO GI data presentation (1/24-26) but we are optimistic about a clinically relevant ~1.5-2 month or better median OS benefit. For the stock, this outcome is important as Abraxane with pomalidomide and apremilast can provide much needed growth diversification away from Revlimid. … Incorporating Abraxane in pancreatic cancer into our model with ~$700MM in 2020 revenue pending the detailed Phase III data and our price target rises to $83 from $81. We assume modest off-label use in the US (already compendia listed) begins in 2013."
Celgene closed at $71.50 on Friday.
Latest Ratings for CELG
|Sep 2014||Cantor Fitzgerald||Maintains||Buy|
|Sep 2014||SunTrust Robinson Humphrey||Initiates Coverage on|
|Jul 2014||Credit Suisse||Maintains||Outperform|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.